Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer

被引：3

作者：

Banna, G. L. ^{[1
]}

Aversa, S. M. L. ^{[1
]}

Crivellari, G. ^{[1
]}

Ghiotto, C. ^{[1
]}

Chiarion-Sileni, V. ^{[1
]}

Monfardini, S. ^{[1
]}

机构：

[1] Ist Oncol Veneto, Div Med Oncol, I-35100 Padua, Italy

来源：

BRITISH JOURNAL OF CANCER | 2006年 / 94卷 / 10期

关键词：

D O I：

10.1038/sj.bjc.6603114

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1550 / 1552

页数：3

共 9 条

[1] Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? [J].

Arnould, L ;

Gelly, M ;

Penault-Llorca, F ;

Benoit, L ;

Bonnetain, F ;

Migeon, C ;

Cabaret, V ;

Fermeaux, V ;

Bertheau, P ;

Garnier, J ;

Jeannin, JF ;

Coudert, B .

BRITISH JOURNAL OF CANCER, 2006, 94 (02) :259-267

[2]

Bishop MR, 2004, HAEMATOLOGICA, V89, P599

[3] Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines [J].

Disis, ML ;

Gooley, TA ;

Rinn, K ;

Davis, D ;

Piepkorn, M ;

Cheever, MA ;

Knutson, KL ;

Schiffman, K .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) :2624-2632

[4] Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 [J].

Gennari, R ;

Menard, S ;

Fagnoni, F ;

Ponchio, L ;

Scelsi, M ;

Tagliabue, E ;

Castiglioni, F ;

Villani, L ;

Magalotti, C ;

Gibelli, N ;

Oliviero, B ;

Ballardini, B ;

Da Prada, G ;

Zambelli, A ;

Costa, A .

CLINICAL CANCER RESEARCH, 2004, 10 (17) :5650-5655

[5]

Reilly RT, 2001, CANCER RES, V61, P880

[6]

Repka T, 2003, CLIN CANCER RES, V9, P2440

[7] Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes [J].

Tsavaris, N ;

Kosmas, C ;

Vadiaka, M ;

Kanelopoulos, P ;

Boulamatsis, D .

BRITISH JOURNAL OF CANCER, 2002, 87 (01) :21-27

[8] HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice [J].

Wolpoe, ME ;

Lutz, ER ;

Ercolini, AM ;

Murata, S ;

Ivie, SE ;

Garrett, ES ;

Emens, LA ;

Jaffee, EM ;

Reilly, RT .

JOURNAL OF IMMUNOLOGY, 2003, 171 (04) :2161-2169

[9]

zum Büschenfelde CM, 2002, CANCER RES, V62, P2244

← 1 →